Vis enkel innførsel

dc.contributor.authorBarkovskaya, Anna
dc.contributor.authorSeip, Kotryna
dc.contributor.authorHilmarsdòttir, Bylgja
dc.contributor.authorMælandsmo, Gunhild Mari
dc.contributor.authorMoestue, Siver Andreas
dc.contributor.authorItkonen, Harri
dc.date.accessioned2019-05-22T11:08:36Z
dc.date.available2019-05-22T11:08:36Z
dc.date.issued2019-04-05
dc.description.abstractPost-translational modifcation of intracellular proteins with a single N-acetylglucosamine sugar (O-GlcNAcylation) regulates signaling, proliferation, metabolism and protein stability. In breast cancer, expression of the enzyme that catalyzes O-GlcNAcylation – O-GlcNAc-transferase (OGT), and the extent of protein O-GlcNAcylation, are upregulated in tumor tissue, and correlate with cancer progression. Here we compare the signifcance of O-GlcNAcylation in a panel of breast cancer cells of different phenotypes. We find a greater dependency on OGT among triple-negative breast cancer (TNBC) cell lines, which respond to OGT inhibition by undergoing cell cycle arrest and apoptosis. Searching for the cause of this response, we evaluate the changes in the proteome that occur after OGT inhibition or knock-down, employing a reverse-phase protein array (RPPA). We identify transcriptional repressor - hairy and enhancer of split-1 (HES1) - as a mediator of the OGT inhibition response in the TNBC cells. Inhibition of OGT as well as the loss of HES1 results in potent cytotoxicity and apoptosis. The study raises a possibility of using OGT inhibition to potentiate DNA damage in the TNBC cells.en_US
dc.description.sponsorshipNational Institutes of Health NCIen_US
dc.descriptionSource at <a href=https://doi.org/10.1038/s41598-019-42153-6>https://doi.org/10.1038/s41598-019-42153-6. </a>en_US
dc.identifier.citationBarkovskaya, A., Seip, K., Hilmarsdòttir, B., Mælandsmo, G.M., Moestue, S.A. & Itkonen, H.M. (2019). O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes. <i>Scientific Reports</i>, 9:5670. https://doi.org/10.1038/s41598-019-42153-6en_US
dc.identifier.cristinIDFRIDAID 1688438
dc.identifier.doi10.1038/s41598-019-42153-6
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/10037/15372
dc.language.isoengen_US
dc.publisherNature Researchen_US
dc.relation.journalScientific Reports
dc.relation.projectIDKreftforeningen: 90393200en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/FRIMEDBIO/239940/Norway/Cancer metabolism: From basic biochemistry to clinical opportunities//en_US
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.titleO-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypesen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel